Skip to content

Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals

Assessment of Oral Caffeine Intake in Reducing the Severity of Acute Migraine Attack Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals: A Randomized Controlled Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07022496
Enrollment
120
Registered
2025-06-15
Start date
2023-04-26
Completion date
2025-08-31
Last updated
2025-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine, Migraine Disease, Migraine Headache, Migraine Headache, With or Without Aura, Migraine, Acute

Brief summary

Caffeine extracted from green tea to abort acute attack of Migraine

Detailed description

Caffeine tablets extracted from green tea can be used as caffeinated drinks to decrease intensity of migraine attacks

Interventions

caffeine tablets

Sumatriptan

Aspirin 250 mg, 81 mg, 75 mg

Paracetamol 250 mg

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

Patients suffering from migraine with aura, migraine without aura, episodic, and chronic migraine according to ICHD-3 diagnosis will be legible for the study.

Exclusion criteria

Patients who have history of any cardiac dysrhythmia, hypertension, ischemic heart disease, active peptic ulcer disease, inflammatory bowel disease, obsessive compulsive disorder, pregnancy, breast-feeding, renal failure, hepatic failure, sleep disorder, mental retardation, and history of substance abuse that prevent them from cooperating with us during the study Patients who had headache due to: Cluster headache, trigeminal neuralgia, glossopharyngeal neuralgia, headache secondary to trauma, cranial disorder, vascular disorder, infection, or mass lesion, will also be excluded

Design outcomes

Primary

MeasureTime frameDescription
To reduce the severity of migraine attackThree yearsusing Visual analogue scale

Secondary

MeasureTime frameDescription
To evaluate the effect of oral caffeine in reducing pain associated with acute migraine attacks among patients attending Headache Clinic, Ain Shams University hospital via Visual analogue scaleThree yearTo assess the pain reduction through visual analogue scale

Countries

Egypt

Contacts

Primary ContactNourhan Nader Elguindy, Masters degree
nourhanelguindy@gmail.com00201128215952
Backup ContactDiaa Marzouk Abdelhamid, PhD
diaamarzouk@yahoo.com00201200678440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026